PMID- 35294068
OWN - NLM
STAT- MEDLINE
DCOM- 20220425
LR  - 20220731
IS  - 1097-0045 (Electronic)
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 82
IP  - 8
DP  - 2022 Jun
TI  - Serum thymidine kinase 1 concentration as a predictive biomarker in prostate 
      cancer.
PG  - 911-916
LID - 10.1002/pros.24335 [doi]
AB  - BACKGROUND: Thymidine kinase 1 (TK1) recycles DNA before cell division. We do not 
      know if baseline blood concentrations of TK1 predict death in prostate cancer 
      within 30 years. Our objective is to determine if there is an association between 
      baseline levels of TK1 and future prostate cancer-specific mortality. METHODS: 
      With a "proof of concept" approach, we performed a nested case-control study 
      among 1782 individuals screened for prostate cancer between 1988 and 1989. The 
      concentration of TK1 was measured in frozen serum from 330 men, 36 of whom have 
      died of prostate cancer. The primary endpoint was prostate cancer-specific 
      mortality and outcomes after 30 years were analyzed using logistic regression 
      modeling odds ratios (Ors). RESULTS: The estimated OR (adjusted for age) for 
      dying from prostate cancer among the men who had a TK1 value in the upper tertile 
      was 2.39 (95% confidence interval 1.02-5.63). The corresponding OR, regardless of 
      the cause of death, was 2.81 (1.24-6.34). CONCLUSIONS: High levels of TK1 
      predicts death in prostate cancer within 30 years of follow-up.
CI  - (c) 2022 The Authors. The Prostate published by Wiley Periodicals LLC.
FAU - Lundgren, Per-Olof
AU  - Lundgren PO
AUID- ORCID: 0000-0001-7976-6962
AD  - Department of Clinical Science, Intervention and Technology, Karolinska Institute 
      and Karolinska University Hospital, Stockholm, Sweden.
FAU - Tribukait, Bernhard
AU  - Tribukait B
AUID- ORCID: 0000-0002-2151-3097
AD  - Department of Oncology-Pathology, Karolinska Institute and University Hospital, 
      Stockholm, Sweden.
FAU - Kjellman, Anders
AU  - Kjellman A
AD  - Department of Clinical Science, Intervention and Technology, Karolinska Institute 
      and Karolinska University Hospital, Stockholm, Sweden.
FAU - Norming, Ulf
AU  - Norming U
AD  - Department of Clinical Science and Education, Sodersjukhuset, Stockholm, Sweden.
FAU - Jagarlmudi, Kiran
AU  - Jagarlmudi K
AD  - Department of Anatomy, Physiology, and Biochemistry, Swedish University of 
      Agricultural Sciences, Uppsala, Sweden.
AD  - Research and Development Division, AroCell AB, Uppsala, Sweden.
FAU - Gustafsson, Ove
AU  - Gustafsson O
AD  - Department of Clinical Science, Intervention and Technology, Karolinska Institute 
      and Karolinska University Hospital, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220316
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (Biomarkers)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.21 (Thymidine Kinase)
RN  - EC 2.7.1.21 (thymidine kinase 1)
SB  - IM
MH  - Biomarkers
MH  - Biomarkers, Tumor
MH  - Case-Control Studies
MH  - Humans
MH  - Male
MH  - *Prostatic Neoplasms
MH  - *Thymidine Kinase
PMC - PMC9311431
OTO - NOTNLM
OT  - prognosis
OT  - prostate cancer
OT  - thymidine kinase
EDAT- 2022/03/17 06:00
MHDA- 2022/04/26 06:00
PMCR- 2022/07/25
CRDT- 2022/03/16 12:14
PHST- 2022/02/16 00:00 [revised]
PHST- 2021/12/01 00:00 [received]
PHST- 2022/03/02 00:00 [accepted]
PHST- 2022/03/17 06:00 [pubmed]
PHST- 2022/04/26 06:00 [medline]
PHST- 2022/03/16 12:14 [entrez]
PHST- 2022/07/25 00:00 [pmc-release]
AID - PROS24335 [pii]
AID - 10.1002/pros.24335 [doi]
PST - ppublish
SO  - Prostate. 2022 Jun;82(8):911-916. doi: 10.1002/pros.24335. Epub 2022 Mar 16.